Finn
TVTX Biotech · Rare disease · Kidney disease · Commercial biotech · Thesis updated November 8, 2026

FILSPARI sales surge past $200 million as CEO plans exit

01 Running thesis

One drug, extended patents, new obstacles

Travere remains a FILSPARI execution story. The drug sells for IgA nephropathy, or IgAN, a kidney disease that can lead to kidney failure. In April 2026, the FDA also approved FILSPARI for focal segmental glomerulosclerosis, or FSGS. That turned one product into a two-market launch, and Q3 2026 sales hit a record $200.2 million on the back of 1,930 patient start forms.

The bull case relies on that momentum and stronger patent protection. Management says more than 100,000 U.S. patients could be eligible across both conditions and sees a $3 billion peak sales chance. New patents extend U.S. exclusivity into 2037, giving the company more time to realize that value. Travere also expects to submit a regulatory application for civorebrutinib in late 2026 to expand the pipeline.

The bear case centers on execution barriers and a major leadership change. CEO Eric Dube is stepping down in December 2026, handing the reins to a new leader during the most critical phase of the FSGS launch. Furthermore, early FSGS prescriptions show wide breadth but lack depth, meaning many doctors are only trying it on a single patient. The company also faces pressure to fix its supply chain after a key manufacturer was targeted by the BIOSECURE Act.

The next test is how the incoming CEO handles these hurdles. Investors will be watching whether the supply chain shift causes delays and whether the sales team can turn trial prescriptions into broader adoption.

Nov 2026▲Q3 results showed FILSPARI sales surpassing $200 million for the first time, supported by new patents extending exclusivity to 2037. CEO Eric Dube announced his departure set for December 2026, adding execution risk.
Aug 2026→Q2 results showed strong FILSPARI sales of $141.1 million and the addition of a new pipeline drug. This was balanced by new risks regarding a key supplier facing BIOSECURE Act limits and an FDA warning over marketing claims.
May 2026▲Management introduced a $3 billion peak sales estimate for FILSPARI across IgAN and FSGS, supported by more than 100,000 eligible U.S. patients. The same call raised the tracking risk because the company will not split patient start forms by indication.
May 2026▲The Q1 2026 filing confirmed full FDA approval of FILSPARI for FSGS on April 13, 2026. It also showed FILSPARI net sales of $105.2 million and set pegtibatinase topline data timing for the second half of 2027.
Feb 2026▲The FY2025 filing showed FILSPARI net sales of $322.0 million for 2025 and confirmed the HARMONY study restart plan. The FSGS review date moved to April 13, 2026, delaying but not ending the catalyst.
Oct 2025▲The FDA said an advisory committee was no longer needed for the FSGS application. That removed a major overhang while Q3 FILSPARI sales of $90.9 million showed continued commercial strength.
Aug 2025▲The FDA accepted the FSGS application and set a January 13, 2026 target action date. Q2 FILSPARI sales of $71.9 million strengthened the launch case.
May 2025▲Travere submitted the FSGS application, turning a possible expansion into a clear regulatory event. Q1 2025 FILSPARI sales reached $55.9 million, while Thiola revenue held at $20.0 million despite generic pressure.
02 Business model

Selling rare disease drugs

Travere makes money mostly by selling approved drugs in the U.S. Its main product is FILSPARI. It also sells Thiola and Thiola EC for cystinuria, a rare disorder that causes kidney stones, though those older drugs face generic competition.

Outside the U.S., Travere licenses sparsentan rights to CSL Vifor and Chugai. Those deals can bring in milestones and royalties, which are high-value revenue streams if partner sales grow.

The model works best when a rare disease drug has strong patent protection, clear payer coverage, and a reliable supply chain. It breaks if launch uptake is slower than expected, if insurers push back, or if reliance on third-party manufacturers causes supply disruptions.

03 Product portfolio

What Travere sells and studies

Growth engine

FILSPARI for IgAN

FILSPARI is approved to slow kidney function decline in adults with IgAN at risk of progression. It is the base of Travere's current growth.

Growth engine

FILSPARI for FSGS

The FDA granted full approval on April 13, 2026, for certain FSGS patients aged 8 years and older. The company recently secured patents extending exclusivity to 2037.

Cash cow

Thiola and Thiola EC

These tiopronin products treat cystinuria. They produced $20.0 million of Q3 2026 net product revenue, but several approved generics make this a shrinking profit support over time.

Option

Civorebrutinib

Licensed from Everest Medicines in June 2026, this oral BTK inhibitor is targeted for rare immune-mediated kidney diseases. A regulatory filing is expected in late 2026.

Option

Pegtibatinase

Pegtibatinase is in the Phase 3 HARMONY study for classical homocystinuria, a rare metabolic disease. Topline data is expected in the second half of 2027.

04 Business segments

Q3 revenue mix

FILSPARI89%growing fast
Tiopronin products9%declining
License and collaboration revenue2%flat

Travere reports as one operating segment. This mix uses Q3 2026 revenue by product and type. FILSPARI grew to 89 percent of total Q3 revenue, showing extreme reliance on a single asset.

05 Risk factors

What could break the story

Leadership transition stumbles

High impact · Medium odds

CEO Eric Dube is leaving the company in December 2026. A change in leadership during the critical dual-indication commercial ramp for FILSPARI could disrupt execution or change capital allocation priorities.

We watchQ4 2026 and Q1 2027 financial results and strategic updates under new CEO Bradley.

FSGS depth fails to materialize

High impact · Medium odds

While early FSGS prescribing shows wide breadth, many doctors have only written scripts for a single patient. If the sales team cannot convince these doctors to prescribe FILSPARI more broadly, the addressable market will be capped.

We watchQuarterly patient start forms and management commentary on prescriber depth.

Supply chain disruptions

High impact · Medium odds

The primary supplier for the active ingredient in FILSPARI was added to a restricted list under the BIOSECURE Act. Travere must qualify alternative sources quickly to avoid supply shortages or higher costs.

We watchProgress on qualifying alternative sparsentan API suppliers.

Marketing claims pullback

Medium impact · Medium odds

The FDA issued an untitled letter in July 2026 over FILSPARI marketing materials. This could slow launch momentum if the company has to pull back its sales messaging or retrain its sales force.

We watchChanges to the FILSPARI visual aids and any slowdown in patient start forms.

Thiola fades faster than planned

Medium impact · High odds

Thiola and Thiola EC still help fund the company. Several generic versions are approved, so sales could erode faster and leave a gap before FILSPARI fully offsets the decline.

We watchQuarterly tiopronin product revenue.
06 Quick answers

In one breath

What does Travere Therapeutics do?

Travere develops and sells drugs for rare kidney and metabolic diseases. Its main product is FILSPARI, which is approved for IgAN and certain FSGS patients.

Why does FILSPARI matter so much to TVTX stock?

FILSPARI is the main growth engine. Management sees a $3 billion peak sales chance across its two indications, so the stock depends heavily on whether that launch keeps growing.

What is the BIOSECURE Act risk for Travere?

The primary supplier for FILSPARI's active ingredient was placed on a restricted list under the BIOSECURE Act. Travere is now working to find and qualify new suppliers to avoid drug shortages.

Why is the leadership transition a risk?

CEO Eric Dube is stepping down in December 2026. The new CEO, Bradley, will need to prove he can maintain commercial execution during a critical growth phase for FILSPARI.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Travere Q3 2026 Form 10-Q
  2. Travere Q3 2026 earnings call transcript
  3. Travere Q2 2026 Form 10-Q
08 Explore the industry

Comparable Biotechnology companies

Companies near Travere Therapeutics, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today